PLYMOUTH, Minn.--(BUSINESS WIRE)--Uromedica, Inc., today announced that it has successfully completed its first US commercial implant of ProACT™ Adjustable Continence Therapy for Men. The procedure was carried out by Dr. Steven Nash in Overland Park, KC. “We have eagerly waited for the ProACT procedure to be available in the United States. Our patients who were part of the ProACT trial have been great ambassadors as to how great the procedure works. They have been a testament to the major improvement in their quality of life. Those patients’ excellent responses have created a wave of referrals from Urologists within our group. We believe the ProACT procedure will revolutionize the minimally invasive treatment of male stress incontinence,” said Nash.
About Post-Prostatectomy Stress Urinary Incontinence and the ProACT Therapy
Men who have undergone radical prostatectomy or transurethral resection of the prostate (TURP) are at risk of Stress Urinary Incontinence (SUI). “Uromedica is excited to deliver the ProACT Therapy to improve the quality of life for men struggling with any level of Stress Urinary Incontinence,” said Tim Cook, PhD, President and CEO of Uromedica. “ProACT has been used to profound effect in Europe for over 15 years. We are happy to finally bring this therapy to men who are in real need of this treatment in the United States.”
The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a filling port. The implantation procedure lasts approximately 30 minutes and can be performed in Ambulatory Surgical Centers or in the Hospital Outpatient setting. The balloons are surgically placed in the area where the prostate was removed or resected and the ports are placed underneath the skin. The fluid-filled balloons provide pressure and support at the bladder neck which protects against accidental leaking of urine that can occur during a sneeze, cough, or physical activity. When there is a need to urinate, passing urine requires only a normal amount of bladder effort. The balloon volume can be adjusted at any time to achieve optimal continence.
Uromedica, Inc. is a privately held, Minnesota-based medical device company that has developed and manufactures a long-term implantable balloon device for the treatment of stress urinary incontinence in men and women. ProACT has been implanted in over 8,500 patients worldwide since 2002. Interested physicians or patients may visit www.proact-for-men.com.